Optimized Oncolytic Virus Panels to Overcome Immune Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic virus therapies face challenges such as individual variability of cancer cells between patients, development of adaptive immunity, and resistance to single virus strains, leading to unpredictable therapeutic responses and potential relapses.
Innovation Solution
Administering a panel of oncolytic viruses that differ in antigenic structure and host-cell requirements, either sequentially or simultaneously, and optimizing viruses through mutagenesis and codon optimization to enhance cancer cell specificity and reduce neutralization by antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a single oncolytic virus strain is used for cancer treatment, then the treatment protocol is simple and safety is maintained, but cancer cell resistance and adaptive immunity development occur leading to treatment failure
Solution Approach 1:
The treatment approach segments the viral therapy into multiple distinct virus strains, each targeting different cancer cell characteristics. This segmentation prevents any single virus from encountering resistance mechanisms that would cause treatment failure, thereby improving reliability while maintaining manageable protocol complexity through structured sequential administration.
Solution Approach 2:
The patent employs parameter changes by alternating between different virus strains with distinct antigenic structures and host-cell requirements. This changes the viral parameters over time to evade adaptive immunity and resistance, improving therapeutic reliability without requiring overly complex treatment protocols.
2Reliability
If multiple oncolytic viruses are administered simultaneously or sequentially, then therapeutic outcomes improve and relapses are reduced, but treatment complexity and administration burden increase
Solution Approach 1:
The patent implements periodic action through sequential administration of multiple virus strains at predetermined time intervals. This periodic approach allows the immune system to respond to each virus strain before the next is introduced, improving therapeutic reliability while keeping the administration protocol manageable through regular timing patterns.
Solution Approach 2:
The treatment protocol segments the viral therapy into distinct administrative phases, with each phase targeting a specific virus strain. This segmentation improves reliability by ensuring comprehensive cancer cell coverage while maintaining clear, manageable administration steps that reduce overall protocol complexity.
3Adaptability or versatility
If oncolytic viruses are used to treat diverse cancer types, then treatment versatility improves, but virus selection and optimization complexity increase
Solution Approach 1:
The patent achieves universality by developing a panel of oncolytic viruses that collectively target multiple cancer types through different mechanisms. Each virus strain is optimized for specific cancer characteristics, creating a multi-functional treatment arsenal that covers diverse malignancies without requiring overly complex selection protocols.
Solution Approach 2:
The patent employs parameter changes by optimizing different virus strains for different cancer types through systematic modification of viral characteristics. This allows versatile cancer type coverage while managing selection complexity through structured optimization parameters that can be applied consistently across different cancer indications.
Data Source
AI summary
Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors.